Newsroom
October 28, 2021
Written by Cliff Despres Institute for Health Promotion Research SAN ANTONIO (Oct. 28, 2021) — The Éxito! Latino Cancer Research Leadership Training program at UT Health San Antonio has been named a winner of Excelencia in Education’s “Examples of Excelencia.” The awards spotlight evidence-based programs that support Latino students in higher education. Éxito! was a […]
October 26, 2021
Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.
October 25, 2021
Dr. Marcela Mazo from the Mays Cancer Center for patient care services within the UT Health San Antonio MD Anderson Cancer Center, was interviewed for this Univision (KWEX-TV) segment where she dispelled myths about breast cancer, including the effect that the COVID-19 vaccine may have on the results of a mammogram, and spoke about the […]
October 25, 2021
Dr. Marcela Mazo from the Mays Cancer Center for patient care services within the UT Health San Antonio MD Anderson Cancer Center, answered questions as part of KSAT 12’s live, Q&A segment. She discussed the signs and symptoms of breast cancer, the importance of breast cancer screenings, the impact the pandemic has had on patients […]
October 22, 2021
What if a daily or weekly blood sample could monitor each patient’s risk of metastasis, indicating the need for aggressive therapy before cancer spread is established? That’s the ultimate goal of studies published by researchers from The University of Texas Health Science Center at San Antonio.
October 19, 2021
Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Oct. 19, 2021) — Cancer that spreads, or metastasizes, to another area of the body is not typically as treatable as the primary tumor from which it originated. Survival from metastatic disease is generally poor. What if a daily or weekly blood sample could monitor each patient’s risk […]
